Market Potential
The Opportunity
The new 2025 TAVR indication for asymptomatic severe aortic stenosis (AS) could:
- •Double the treatable AS population
- •Double the existing $7B TAVR market
Yet most of these asymptomatic patients remain undetected under today's care pathways.
Valvular aortic stenosis in adults.
Average course (postmortem data).*
Our low-cost, AI screening device can detect symptomatic and asymptomatic AS patients with a 5-minute test.
*Dr. Eugene Braunwald: https://doi.org/10.1161/CIRCULATIONAHA.118.033408
**Dr. Sreekanth Vemulapalli: https://www.sciencedirect.com/science/article/pii/S2474870625003343